GlassScriptPhysician profile
Carla Christo
NPI 1730810466
$7,183.57
in general payments reported to CMS, 2019-2025
53 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,997 · 2024: $3,493 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,203 · Long Term Medical Supply Or Device Loan: $1,881 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,202.69 |
| Long Term Medical Supply Or Device Loan | $1,880.89 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,207.00 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $711.11 | 2023-2025 | Enhertu, Imfinzi, Calquence |
| Seagen INC. | $439.24 | 2023 | Adcetris, Padcev, Tukysa |
| Incyte Corporation | $337.52 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Merck Sharp & Dohme LLC | $311.47 | 2023-2024 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $222.43 | 2023-2025 | Erleada, Rybrevant, Akeega |
| Takeda Pharmaceuticals U.S.A., INC. | $184.57 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Celgene Corporation | $183.65 | 2023-2025 | Reblozyl |
| Daiichi Sankyo INC. | $183.54 | 2023-2025 | Enhertu, Injectafer |
| Eisai INC. | $172.37 | 2023-2025 | |
| Pfizer INC. | $146.12 | 2023-2024 | |
| Beigene USA, INC. | $142.15 | 2023-2025 | Brukinsa |
| Glaxosmithkline, LLC. | $127.79 | 2023-2024 | Zejula, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $127.01 | 2023-2024 | Libtayo |
| Emd Serono, INC. | $122.02 | 2023-2025 | Bavencio |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $114.76 | 2023-2024 | Retevmo, Jaypirca, Verzenio |
| Genzyme Corporation | $114.59 | 2023-2024 | |
| Tersera Therapeutics LLC | $96.40 | 2023-2025 | Zoladex |
| Astellas Pharma US INC | $95.29 | 2023-2024 | Padcev, Xospata |
| Sobi, INC | $86.31 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $80.75 | 2023-2024 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $75.04 | 2023-2025 | |
| Beone Medicines USA, INC. | $67.61 | 2025 | Tevimbra, Brukinsa |
| Array Biopharma INC | $65.67 | 2023-2025 | Lorbrena, Mektovi, Braftovi |
| Taiho Oncology, INC. | $46.14 | 2024 | |
| Geron Corporation | $45.96 | 2025 | Rytelo |
| Alnylam Pharmaceuticals INC. | $44.76 | 2023 | Onpattro, Givlaari |
| Caris Mpi, INC. | $44.65 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $42.48 | 2023 | Epkinly, Imbruvica |
| Jazz Pharmaceuticals INC. | $40.07 | 2024 | |
| Mirati Therapeutics, INC. | $33.86 | 2023-2024 | Krazati |
| Agios Pharmaceuticals, INC. | $31.13 | 2025 | Pyrukynd |
| Amgen INC. | $29.37 | 2023 | Lumakras |
| Alexion Pharmaceuticals, INC. | $26.50 | 2025 | Ultomiris |
| Gilead Sciences, INC. | $25.58 | 2025 | Trodelvy |
| Abbvie INC. | $25.48 | 2024 | |
| Apellis Pharmaceuticals, INC. | $24.36 | 2023 | Empaveli |
| Recordati_rare_diseases_inc. | $23.38 | 2025 | Enjaymo |
| Karyopharm Therapeutics INC. | $23.24 | 2024 | Xpovio |
| Pharmacosmos Therapeutics INC. | $22.23 | 2024 | Cosela |
| Genmab U.S., INC. | $21.67 | 2023 | Epkinly |
| Tempus Ai, INC | $21.31 | 2025 | Xt Cdx |
| Adc Therapeutics America, INC. | $20.84 | 2025 | |
| G1 Therapeutics, INC. | $20.10 | 2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $19.75 | 2024 | |
| Stemline Therapeutics INC. | $19.44 | 2023 | Orserdu |
| Exelixis INC. | $19.22 | 2024 | Cabometyx |
| Novocure INC. | $17.65 | 2025 | Optune Lua (Novottf-200t) |
| Adaptive Biotechnologies Corporation | $17.60 | 2024 | Clonoseq |
| Puma Biotechnology, INC. | $15.99 | 2025 | |
| Servier Pharmaceuticals LLC | $15.83 | 2025 | |
| Immunogen, INC. | $15.40 | 2024 | Elahere |
| Acrotech Biopharma INC. | $15.17 | 2023 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Christo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.